Biological Activity of Cannabis sativa L. Extracts Critically Depends on Solvent Polarity and Decarboxylation
Open Access
- 20 October 2020
- journal article
- research article
- Published by MDPI AG in Separations
- Vol. 7 (4) , 56
Abstract
Minor cannabinoid and non-cannabinoid molecules have been proposed to significantly contribute to the pharmacological profile of cannabis extracts. Phytoplant Research has developed highly productive cannabis cultivars with defined chemotypes, as well as proprietary methods for the extraction and purification of cannabinoids. Here, we investigate the effect of solvent selection and decarboxylation on the composition and pharmacological activity of cannabis extracts. A library of forty cannabis extracts was generated from ten different cannabis cultivars registered by Phytoplant Research at the EU Community Plant Variety Office. Plant material was extracted using two different solvents, ethanol and hexane, and crude extracts were subsequently decarboxylated or not. Cannabinoid content in the resulting extracts was quantified, and biological activity was screened in vitro at three molecular targets involved in hypoxia and inflammation (NF-κB, HIF-1α and STAT3). Changes in transcriptional activation were strongly associated to solvent selection and decarboxylation. Two decarboxylated extracts prepared with hexane were the most potent at inhibiting NF-κB transcription, while HIF-1α activation was preferentially inhibited by ethanolic extracts, and decarboxylated extracts were generally more potent at inhibiting STAT3 induction. Our results indicate that solvent selection and proper decarboxylation represent key aspects of the standardized production of cannabis extracts with reproducible pharmacological activity.Keywords
This publication has 36 references indexed in Scilit:
- Revisiting STAT3 signalling in cancer: new and unexpected biological functionsNature Reviews Cancer, 2014
- Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget EffectPLOS ONE, 2013
- Activation of STAT3 is involved in neuroprotection by electroacupuncture pretreatment via cannabinoid CB1 receptors in ratsBrain Research, 2013
- Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulatorsProgress in Lipid Research, 2013
- Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effectsBritish Journal of Pharmacology, 2011
- Cannabinoids Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Inhibit the Lipopolysaccharide-activated NF-κB and Interferon-β/STAT Proinflammatory Pathways in BV-2 Microglial CellsJournal of Biological Chemistry, 2010
- CB2 cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusionJournal of Molecular and Cellular Cardiology, 2009
- Denbinobin inhibits nuclear factor-κB and induces apoptosis via reactive oxygen species generation in human leukemic cellsBiochemical Pharmacology, 2009
- Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesisNeuro-Oncology, 2005
- The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-κB)Neuropharmacology, 2004